InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Monte Rosa Therapeutics, Inc.

GLUE Clue Score47
United States Fiscal year ends December CIK 0001826457
$10.30 -0.19% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $10.30 −46.74% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 24 Jun 2021. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2020Operating income−28.0Net income−35.9Fiscal year 2021Operating income−72.9Net income−74.0EPS, diluted−2.96Fiscal year 2022Operating income−112.4Net income−108.5EPS, diluted−2.30Fiscal year 2023Revenue0.0Operating income−143.3Net income−135.4EPS, diluted−2.63Fiscal year 2024Revenue75.6Operating income−81.1Net income−72.7EPS, diluted−0.98Fiscal year 2025Revenue123.7 +63.5%Operating income−54.2Net income−38.6EPS, diluted−0.46
FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a 0.0 75.6 123.7
Growth +63.5%
Operating income −28.0 −72.9 −112.4 −143.3 −81.1 −54.2
Net income −35.9 −74.0 −108.5 −135.4 −72.7 −38.6
Growth
EPS, diluted n/a −2.96 −2.30 −2.63 −0.98 −0.46

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Fiscal year 2024Operating margin−107.3%Net margin−96.1%Free cash flow margin50.3%Fiscal year 2025Operating margin−43.8%Net margin−31.2%Free cash flow margin−22.2%
FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a −107.3% −43.8%
Net margin n/a n/a n/a n/a −96.1% −31.2%
Free cash flow margin n/a n/a n/a n/a 50.3% −22.2%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2020Operating cash flow−23.1Capital expenditure−3.4Free cash flow−26.4Fiscal year 2021Operating cash flow−59.4Capital expenditure−9.7Free cash flow−69.1Dividends paid0.0Fiscal year 2022Operating cash flow−92.5Capital expenditure−12.9Free cash flow−105.4Dividends paid0.0Fiscal year 2023Operating cash flow−43.8Capital expenditure−19.0Free cash flow−62.8Dividends paid0.0Fiscal year 2024Operating cash flow42.0Capital expenditure−4.0Free cash flow38.0Dividends paid0.0Fiscal year 2025Operating cash flow−22.8Capital expenditure−4.7Free cash flow−27.5 −172.3%Dividends paid0.0
FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −23.1 −59.4 −92.5 −43.8 42.0 −22.8
Capital expenditure −3.4 −9.7 −12.9 −19.0 −4.0 −4.7
Free cash flow −26.4 −69.1 −105.4 −62.8 38.0 −27.5
Growth −172.3%
Dividends paid n/a 0.0 0.0 0.0 0.0 0.0

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2020Cash41.7Shareholders’ equity−48.7Fiscal year 2021Cash346.1Shareholders’ equity347.5Fiscal year 2022Cash54.9Shareholders’ equity271.4Fiscal year 2023Cash128.1Shareholders’ equity179.3Fiscal year 2024Cash224.3Shareholders’ equity222.9Fiscal year 2025Cash129.9Shareholders’ equity233.1
FY2020FY2021FY2022FY2023FY2024FY2025
Cash 41.7 346.1 54.9 128.1 224.3 129.9
Shareholders’ equity −48.7 347.5 271.4 179.3 222.9 233.1

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022† 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a n/a n/a 0.0 75.6 123.7
Growth +63.5%
24.0 57.2 85.1 111.3 121.6 141.5
4.0 15.7 27.3 32.0 35.2 36.4
−28.0 −72.9 −112.4 −143.3 −81.1 −54.2
Growth
n/a n/a −108.5 −135.0 −70.1 −39.7
n/a n/a 0.0 0.3 2.6 −1.1
−35.9 −74.0 −108.5 −135.4 −72.7 −38.6
Growth
Per share
n/a −2.96 −2.30 −2.63 −0.98 −0.46
n/a −2.96 −2.30 −2.63 −0.98 −0.46
Growth
n/a 25.0 47.2 51.4 73.9 83.1
n/a 25.0 47.2 51.4 73.9 83.1
Growth +88.9% +8.8% +43.8% +12.4%

† The diluted share count jumps at 2022, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 6 of 6 years on file.